Study Enrollment


Your details will not be published or shared.

Clinical Trial

TAEK-VAC-HerBy-001: Phase 1/2 expansion cohorts trial of intravenous administration of TAEK-VAC-HerBy vaccine alone and in combination with HER2- and PD-1/PD-L1 antibodies in patients with advanced HER2-expressing cancer

The purpose of this study is to test the safety of TAEK-VAC-HerBy vaccine given intravenously to people with advanced cancer. The vaccine is manufactured by Bavarian Nordic (BN) and is known as TAEK-VAC-HerBy. The vaccine tested in this study is made up of a virus called Modified Vaccinia Ankara-BN (MVA-BN) virus. The virus does not have the ability to grow in hman cells, instead it releases an immune response without the risk of viral infection. The goal is to teach the immune system to kill the tumor cells that express the Brachyury protein and the HER2 protein to help stop tumor cell growth and metatisis.


Eligibility Criteria

  • Eligibility criteria: Men and women at least 18 years of age or older; Must have a metastatic or recurrent locally advanced malignant tumor, histologically documented; Subjects will be excluded if they have received an investigational agent within 28 days of the first planned dose of TVH vaccine.

Contact Information

    Joanne Huff, RN, MSN

    (706) 721-5177

   johuff@augusta.edu

RESEARCH. INNOVATION. DISCOVERY.